Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VERVE-102 in ASCVD
NCT07839936Phase 2Not yet recruiting
- Sponsor
- Verve Therapeutics
- Start
- Oct 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VERVE-102 in atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia (4 arms), sponsored by Verve Therapeutics. Primary endpoint: Percent Change from Baseline in Low-Density Lipoprotein-Cholesterol at Day 90. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
VERVE-102
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)hypercholesterolemia
Beyond the preview
Go deeper on NCT07839936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07839936.